Skip to search formSkip to main contentSkip to account menu

MLN 8237

Known as: Aurora A Kinase Inhibitor MLN8237, MLN-8237, MLN8237 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

AzepinesPyrimidines

Narrower (1)

alisertib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Applications of Pathology-Assisted Image Analysis of Immunohistochemistry-Based Biomarkers in Oncology
Immunohistochemistry-based biomarkers are commonly used to understand target inhibition in key cancer pathways in preclinical… 
2014
2014
Long Residence Times Revealed by Aurora A Kinase‐Targeting Fluorescent Probes Derived from Inhibitors MLN8237 and VX‐689
We report the development of three fluorescent probes for protein kinase Aurora A that are derived from the well‐known inhibitors… 
2013
2013
Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
Alisertib (MLN8237) is an investigational potent Aurora A kinase inhibitor currently under clinical trials for hematological and… 
2013
2013
Response to MLN8237 in Pancreatic Cancer Is Not Dependent on RalA Phosphorylation
The high prevalence of KRAS mutations and importance of the RalGEF–Ral pathway downstream of activated K-ras in pancreatic ductal… 
2012
2012
Phase I/II study of weekly paclitaxel with or without MLN8237 (alisertib), an investigational aurora A kinase inhibitor, in patients with recurrent epithelial ovarian, fallopian tube, or primary…
5021 Background: Preclinical data indicate that inhibiting aurora A kinase (AAK), a key mitotic regulator, in OC can enhance the… 
2010
2010
Phase 2 Study of MLN8237, An Investigational Aurora A Kinase (AAK) Inhibitor In Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS)
Abstract 3273 Background: AAK is essential for mitotic progression and is amplified or overexpressed in AML and other hematologic… 
2009
2009
Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MLN8237, a novel selective aurora A kinase (AAK) inhibitor, in patients (pts) with advanced solid tumors.
2565 Background: MLN8237 is a second-generation, selective AAK inhibitor, designed to avoid benzodiazepine-like effects… 
2009
2009
Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models.
8553 Background: Aurora A kinase is a serine/threonine protein kinase that is essential for the successful transit of cells… 
2008
2008
280 POSTER Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States
2008
2008
MLN8237: an orally active small molecule inhibitor of Aurora A kinase in phase I clinical trials
237 Aurora A kinase regulates the activity of a number of proteins essential to the proper execution of mitosis. Perturbation of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)